Short-term outcomes of COVID-19 and risk factors for progression

Li Long; Xiansheng Zeng; Xu Zhang; Wei Xiao; E Guo; Wenzhi Zhan; Xuejiao Yang; Chunyan Li; Caiyun Wu; Tingting Xu; Chen Zhan; Yuehan Chen; Mei Jiang; Nanshan Zhong; Kefang Lai

doi:10.1183/13993003.00990-2020

Short-term outcomes of COVID-19 and risk factors for progression

Eur Respir J. 2020 May 27;55(5):2000990. doi: 10.1183/13993003.00990-2020. Print 2020 May.

Authors

Li Long^{1

2}, Xiansheng Zeng^{3

2}, Xu Zhang^{4

2}, Wei Xiao^{4

2}, E Guo^{3

2}, Wenzhi Zhan¹, Xuejiao Yang³, Chunyan Li⁴, Caiyun Wu³, Tingting Xu¹, Chen Zhan¹, Yuehan Chen¹, Mei Jiang¹, Nanshan Zhong¹, Kefang Lai¹

Affiliations

¹ State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
² These authors contributed equally to this article.
³ Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
⁴ The First People's Hospital of Jingzhou, Jingzhou, China.

Abstract

With a median (IQR) follow-up time of 24.0 (17.5–30.0) days, progression occurred in 19.6% moderate, 27.8% severe and 66.7% critical COVID-19. Neutrophil-to-lymphocyte ratio ≥2.973, age ≥50 years, male sex and comorbidity were associated with progression. https://bit.ly/3crsJr0

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Betacoronavirus
COVID-19
China
Comorbidity
Coronavirus Infections
Humans
Pandemics
Pneumonia, Viral
Risk Factors
SARS-CoV-2